Phase I/II study of sorafenib with anastrozole in patients with hormone receptor positive aromatase inhibitor resistant metastatic breast cancer

Breast Cancer Research and Treatment

Volumn 125, Issue 1, 2011, Pages 137-143

  Isaacs, Claudine ^a   Herbolsheimer, Pia ^a   Liu, Minetta C ^a   Wilkinson, Mary ^b   Ottaviano, Yvonne ^c   Chung, Gina G ^d   Warren, Robert ^a   Eng Wong, Jennifer ^a   Cohen, Philip ^a   Smith, Karen L ^e   Creswell, Karen ^a   Novielli, Antonella ^a   Slack, Rebecca ^a  

^a GEORGETOWN UNIVERSITY   (United States)

^b Fairfax Northern Virginia Hematology Oncology   (United States)

^c Franklin Square Hospital Center   (United States)

^d YALE CANCER CENTER   (United States)

^e WASHINGTON CANCER INSTITUTE   (United States)

Author keywords

Anastrozole; Aromatase inhibitor; Breast cancer; Endocrine resistance; Sorafenib

Indexed keywords

ANASTROZOLE; AROMATASE INHIBITOR; CD133 ANTIGEN; CD146 ANTIGEN; ESTROGEN RECEPTOR; EXEMESTANE; LETROZOLE; PROGESTERONE RECEPTOR; SORAFENIB; TAMOXIFEN;

ACNE; ADULT; AGED; ALOPECIA; ANOREXIA; ARTHRALGIA; ARTICLE; BREAST CANCER; CANCER HORMONE THERAPY; CANCER SURVIVAL; CHEMOSENSITIVITY; CHEMOTHERAPY INDUCED EMESIS; CHILL; CLINICAL ARTICLE; CONSTIPATION; DEHYDRATION; DIARRHEA; DRUG DOSE REDUCTION; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG RESPONSE; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; ENDOTHELIAL PROGENITOR CELL; ENDOTHELIUM CELL; FATIGUE; FEMALE; HAND FOOT SYNDROME; HUMAN; HYPERTENSION; HYPOPHOSPHATEMIA; HYPOTENSION; INFECTION; JOINT FUNCTION; LIVER FUNCTION TEST; METASTASIS; MUCOSA INFLAMMATION; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; PAIN; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PLEURA EFFUSION; POSTMENOPAUSE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PRURITUS; RIGOR; SENSORY NEUROPATHY; SIDE EFFECT; THROMBOSIS; URTICARIA; WEIGHT REDUCTION;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AROMATASE INHIBITORS; BENZENESULFONATES; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; DRUG RESISTANCE, NEOPLASM; ENDOTHELIAL CELLS; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; NITRILES; PROTEIN KINASE INHIBITORS; PYRIDINES; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; STEM CELLS; TIME FACTORS; TREATMENT OUTCOME; TRIAZOLES; UNITED STATES;

EID: 78651101402     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-010-1226-z     Document Type: Article

References (29)

1. A Jemal R Siegel E Ward, et al. 2009 Cancer statistics CA Cancer J Clin 59 225 249 10.3322/caac.20006 19474385
2. I Jatoi A Tsimelzon H Weiss, et al. 2005 Hazard rates of recurrence following diagnosis of primary breast cancer Breast Cancer Res Treat 89 173 178 10.1007/s10549-004-1722-0 15692760 (Pubitemid 40249051)
3. I Jatoi BE Chen WF Anderson, et al. 2007 Breast cancer mortality trends in the United States according to estrogen receptor status and age at diagnosis J Clin Oncol 25 1683 1690 10.1200/JCO.2006.09.2106 17404367 (Pubitemid 46797948)
4. S Dawood K Broglio AM Gonzalez-Angulo, et al. 2008 Trends in survival over the past two decades among white and black patients with newly diagnosed stage IV breast cancer J Clin Oncol 26 4891 4898 10.1200/JCO.2007.14.1168 18725649
5. Chlebowski R, Cuzick J, Amakye D et al (2009) Clinical perspectives on the utility of aromatase inhibitors for the adjuvant treatment of breast cancer. Breast 18(suppl 2):S1-S11
6. J Shou S Massarweh CK Osborne, et al. 2004 Mechanisms of tamoxifen resistance: increased estrogen receptor-Her2/neu cross-talk in ER/HER2-positive breast cancer J Natl Cancer Inst 96 926 935 1:CAS:528:DC%2BD2cXltVWmtLY%3D 10.1093/jnci/djh166 15199112
7. S Kato H Endoh Y Masuhiro, et al. 1995 Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase Science 270 1491 1494 1:CAS:528:DyaK2MXps12hs7o%3D 10.1126/science.270.5241.1491 7491495
8. A Adeyinka Y Nui T Cherlet, et al. 2002 Activated mitogen-activated protein kinase expression during human breast tumorigenesis and breast cancer progression Clin Cancer Res 8 1747 1753 1:CAS:528:DC%2BD38Xlt1CrtLo%3D 12060612
9. LS Callans H Naama M Khandelwal, et al. 1995 Raf-1 protein expression in human breast cancer cells Ann Surg Oncol 2 38 42 1:STN:280:DyaK2M7js1Smsg%3D%3D 10.1007/BF02303700 7834453
10. FC Von Lintig AD Dreilinger NM Varki, et al. 2000 Ras activation in human breast cancer Breast Cancer Res Treat 62 51 62 10.1023/A:1006491619920 (Pubitemid 30609563)
11. SR Johnston 2010 New strategies in estrogen receptor-positive breast cancer Clin Cancer Res 16 1979 1987 1:CAS:528:DC%2BC3cXktFygu7o%3D 10.1158/1078-0432.CCR-09-1823 20332324
12. SM Wilhelm C Carter L Tang, et al. 2004 BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis Cancer Res 64 7099 7109 1:CAS:528:DC%2BD2cXotFalsbk%3D 10.1158/0008-5472.CAN-04-1443 15466206 (Pubitemid 39331023)
13. B Escudier T Eisen WM Stadler, et al. 2007 Sorafenib in advanced clear-cell renal-cell carcinoma N Engl J Med 356 125 134 1:CAS:528: DC%2BD2sXksVKitg%3D%3D 10.1056/NEJMoa060655 17215530 (Pubitemid 46089673)
14. JM Llovet S Ricci V Mazzaferro, et al. 2008 Sorafenib in advanced hepatocellular carcinoma N Engl J Med 359 4 378 390 1:CAS:528: DC%2BD1cXovFWjsL8%3D 10.1056/NEJMoa0708857 18650514
15. G Bianchi S Loibl C Zamagni, et al. 2009 Phase II multicenter, uncontrolled trial of sorafenib in patients with metastatic breast cancer Anti Cancer Drugs 20 616 624 1:CAS:528:DC%2BD1MXotFCgtr4%3D 10.1097/CAD. 0b013e32832b2ea0 19739318
16. A Moreno-Aspitia RF Morton DW Hillman, et al. 2009 Phase II trial of sorafenib in patients with metastatic breast cancer previously exposed to anthracyclines or taxanes: North Central Cancer Treatment Group and Mayo Clinic Trial No. 336 J Clin Oncol 27 11 15 1:CAS:528:DC%2BD1MXhs1Gnsb8%3D 10.1200/JCO.2007.15.5242 19047293
17. Baselga J, Grupo Español de Estudio Tratamiento y Otras Estrategias Experimentales en Tumores Sólidos, Roché H et al (2009) SOLTI-0701: a double-blind, randomized, phase 2b study evaluating the efficacy and safety of sorafenib (SOR) compared to placebo (PL) when administered in combination with capecitabine (CAP) in patients (pts) with locally advanced (adv) or metastatic (met) breast cancer (Bc). In: Presented at the 15th European Cancer Organization (ECCO) and 34th European Society for Medical Oncology (ESMO) Multidisciplinary Congress, Berlin, Germany, September 20-24, 2009
18. Gradishar WJ, Kaklamani V, Sahoo TP et al (2009) A double-blind, randomized, placebo-controlled, phase IIb study evaluating the efficacy and safety of sorafenib in combination with paclitaxel as first-line therapy in patients with locally recurrent or metastatic breast cancer. In: Presented at the San Antonio Breast Cancer Symposium, San Antonio, TX, December 8-12, 2009
19. Bonelli MA, Fumarola C, Alfieri RR et al (2010) Synergistic activity of letrozole and sorafenib on breast cancer cells. Breast Cancer Res Treat. doi: 10.1007/s10549-009-0714-5
20. R Simon 1989 Optimal two-stage designs for phase II clinical trials Control Clin Trials 10 1 10 1:STN:280:DyaL1M7ps1SjsQ%3D%3D 10.1016/0197-2456(89) 90015-9 2702835 (Pubitemid 19099520)
21. P Therasse SG Arbuck EA Eisenhauer, et al. 2000 New guidelines to evaluate the response to treatment in solid tumors European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92 205 216 1:STN:280:DC%2BD3c7it1Gitg%3D%3D 10.1093/jnci/92.3.205 10655437
22. P Mancuso P Antoniotti J Quarna, et al. 2009 Validation of a standardized method for enumerating circulating endothelial cells and progenitors: flow cytometry and molecular and ultrastructural analyses Clin Cancer Res 15 267 273 1:CAS:528:DC%2BD1MXhs1ersQ%3D%3D 10.1158/1078-0432.CCR-08-0432 19118054
23. M Steurer J Kern M Zitt, et al. 2008 Quantification of circulating endothelial and progenitor cells: comparison of quantitative PCR and four-channel flow cytometry BMC Res Notes 1 71 10.1186/1756-0500-1-71 18755033
24. EL Kaplan P Meier 1958 Nonparametric estimation from incomplete observations J Am Stat Assoc 53 457 481 10.2307/2281868
25. Snedecor G, Cochran W (1989) Statistical methods, 8th edn. Iowa State University Press, Ames Iowa, pp 251-252
26. JM Lee GA Sarosy CM Annunziata, et al. 2010 Combination therapy: intermittent sorafenib with bevacizumab yields activity and decreased toxicity Br J Cancer 102 495 499 1:CAS:528:DC%2BC3cXhsVSrs7w%3D 10.1038/sj.bjc.6605514 20051952
27. Vroling L, Lind JS, de Haas RR et al (2009) CD133+ circulating haematopoietic progenitor cells predict for response to sorafenib plus erlotinib in non-small cell lung cancer patients. Br J Cancer 1-8
28. A Calleri A Bono V Bagnardi, et al. 2009 Predictive potential of angiogenic growth factors and circulating endothelial cells in breast cancer patients receiving metronomic chemotherapy plus bevacizumab Clin Cancer Res 15 7652 7657 1:CAS:528:DC%2BD1MXhsFGgurvE 10.1158/1078-0432.CCR-09-1493 19996223
29. AM Schultheis G Lurje KE Rhodes, et al. 2008 Polymorphisms and clinical outcomes in recurrent ovarian cancer treated with cyclophoshamide and bevacizumab Clin Cancer Res 14 7554 7563 1:CAS:528:DC%2BD1cXhtlylur3K 10.1158/1078-0432.CCR-08-0351 19010874